Jul 7, 2026 08:01AM
Jul 7, 2026 08:00AM
May 5, 2026 04:30PM
Apr 17, 2026 04:05PM
Apr 17, 2026 04:05PM
Mar 24, 2026 09:50AM
Mar 23, 2026 08:01AM Theriva Biologics gets FDA agreement on phase 3 pancreatic cancer trial
Mar 23, 2026 08:00AM
Mar 23, 2026 08:00AM
Mar 12, 2026 08:00AM
Feb 3, 2026 08:01AM
Feb 3, 2026 08:00AM
Dec 29, 2025 08:00AM
Dec 29, 2025 08:00AM Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Nov 12, 2025 08:00AM
May 27, 2025 08:01AM
May 27, 2025 08:00AM
May 7, 2025 07:00AM
May 7, 2025 07:00AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with
Mar 6, 2025 04:10PM
Dec 5, 2024 08:00AM
Dec 5, 2024 08:00AM
Nov 12, 2024 08:00AM
Oct 16, 2024 08:02AM
Oct 16, 2024 08:00AM
Sep 23, 2024 08:00AM Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Aug 13, 2024 08:00AM
Jul 31, 2024 08:16AM
Jul 31, 2024 08:15AM
May 23, 2024 08:15AM
May 23, 2024 08:15AM
Nov 13, 2023 08:00AM
Aug 8, 2023 08:00AM Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
Jun 27, 2023 04:14PM
Jun 27, 2023 04:10PM
May 11, 2023 08:00AM
Mar 30, 2023 08:00AM
Jan 17, 2023 08:00AM
Nov 10, 2022 04:45PM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All